Timber pharmaceuticals announces 50% enrollment in phase 2b control study in congenital ichthyosis

- study is evaluating tmb-001 (topical isotretinoin) in subtypes of rare genetic keratinization disorder
TMBR Ratings Summary
TMBR Quant Ranking